<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VANDETANIB- vandetanib tablet </strong><br>AstraZeneca Pharmaceuticals LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use vandetanib safely and effectively. See full prescribing information for vandetanib.<br>Initial U.S. Approval: 2011</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: QT PROLONGATION, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">TORSADES DE POINTES</span>, AND <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">SUDDEN DEATH</span></span></h1>
<h1 class="Warning">See full prescribing information for complete boxed warning. Vandetanib can prolong the QT interval. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have been reported in patients receiving vandetanib. Vandetanib should not be used in patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and/or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> must be corrected prior to vandetanib administration and should be periodically monitored. Drugs known to prolong the QT interval should be avoided. If a drug known to prolong the QT interval must be administered, more frequent ECG monitoring is recommended.  Given the half-life of 19 days, ECGs should be obtained to monitor the QT at baseline, at 2-4 weeks and 8-12 weeks after starting treatment with vandetanib and every 3 months thereafter.  Following any dose reduction for QT prolongation, or any dose interruptions greater than 2 weeks, QT assessment should be conducted as described above. Because of the 19-day half-life, adverse reactions including a prolonged QT interval may not resolve quickly.  Monitor appropriately. Only prescribers and pharmacies certified through the vandetanib REMS education program are able to prescribe and dispense vandetanib <a href="#rowellsl1302708976108">(5.15)</a>.</h1>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: QT PROLONGATION, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">TORSADES DE POINTES</span>, AND <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">SUDDEN DEATH</span></span></h1>
<h1 class="Warning">See full prescribing information for complete boxed warning. Vandetanib can prolong the QT interval. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have been reported in patients receiving vandetanib. Vandetanib should not be used in patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and/or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> must be corrected prior to vandetanib administration and should be periodically monitored. Drugs known to prolong the QT interval should be avoided. If a drug known to prolong the QT interval must be administered, more frequent ECG monitoring is recommended.  Given the half-life of 19 days, ECGs should be obtained to monitor the QT at baseline, at 2-4 weeks and 8-12 weeks after starting treatment with vandetanib and every 3 months thereafter.  Following any dose reduction for QT prolongation, or any dose interruptions greater than 2 weeks, QT assessment should be conducted as described above. Because of the 19-day half-life, adverse reactions including a prolonged QT interval may not resolve quickly.  Monitor appropriately. Only prescribers and pharmacies certified through the vandetanib REMS education program are able to prescribe and dispense vandetanib <a href="#rowellsl1302708976108">(5.15)</a>.</h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Vandetanib is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Use of vandetanib in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of vandetanib.  (<a href="#section-1">1</a>)</p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li><p class="Highlighta">300 mg once daily (<a href="#rowellsl1302709585483">2</a>) </p></li>
<li><p class="Highlighta">Vandetanib may be taken with or without food. </p></li>
<li><p class="Highlighta">Dosage reduction may be necessary in the event of severe toxicities or QTc interval prolongation. (<a href="#rowellsl1302709599311">2.1</a>) </p></li>
<li><p class="Highlighta">The starting dose should be reduced to 200 mg in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">100 mg and 300 mg tablets (<a href="#rowellsl1302709835608">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li><p class="Highlighta">Do not use in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>.  (<a href="#section-4">4</a>)</p></li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><p class="Highlighta">Prolonged QT Interval, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have been reported. Monitor electrocardiograms and levels of serum potassium, calcium, magnesium and TSH at baseline, 2-4 weeks and 8-12 weeks after starting treatment with vandetanib, and every 3 months thereafter and following dose adjustments. Dose reduce as appropriate (<a href="#rowellsl1302709599311">2.1</a>, <a href="#rowellsl1302709629546">5.1</a>). </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been observed. Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may prompt permanent discontinuation of vandetanib (<a href="#rowellsl1302709599311">2.1</a>, <a href="#rowellsl1302710037155">5.2</a>).  </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span>, resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported. Interrupt vandetanib and investigate unexplained <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.  Appropriate measures should be taken for ILD (<a href="#rowellsl1302709599311">2.1</a>, <a href="#rowellsl1302710080858">5.3</a>).  </p></li>
<li><p class="Highlighta">Ischemic cerebrovascular events, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span>, have been observed (<a href="#rowellsl1302709599311">2.1,</a><a href="#rowellsl1302710113874">5.4</a>, <a href="#rowellsl1302710125889">5.5</a>, <a href="#rowellsl1302710136077">5.6</a>, <a href="#rowellsl1302710146139">5.7</a>, <a href="#rowellsl1302710158577">5.8</a>, <a href="#rowellsl1302709642233">5.9</a>, <a href="#rowellsl1302710180717">5.10</a>). </p></li>
<li><p class="Highlighta">Vandetanib can cause fetal harm when administered to a pregnant woman. Women should be advised to avoid pregnancy while receiving vandetanib and for four months following treatment (<a href="#rowellsl1302710192655">5.14</a>, <a href="#rowellsl1302710210077">8.1</a>).  </p></li>
<li><p class="Highlighta">Because of the risks of QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, vandetanib is available only through a restricted distribution program called the Vandetanib REMS Program.  Only prescribers and pharmacies certified with the program are able to prescribe and dispense vandetanib.  To learn about the specific REMS requirements and to enroll in the Vandetanib REMS Program call 1-800-236–9933 or visit www.vandetanibrems.com (<a href="#rowellsl1302708976108">5.15</a>). </p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse drug reactions (&gt;20%) seen with vandetanib have been <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.  The most common laboratory abnormalities (&gt;20%) were decreased calcium, increased ALT, and decreased glucose  (<a href="#rowellsl1302709599311">2.1</a>. <a href="#rowellsl1302710037155">5.2</a>, <a href="#rowellsl1302710146139">5.7</a>, <a href="#rowellsl1302709642233">5.9</a>, <a href="#rowellsl1302710996139">6.1</a>).  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, Contact AstraZeneca 1–800–236–9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">The concomitant use of known strong CYP 3A4 inducers may reduce drug levels of vandetanib and should be avoided (<a href="#rowellsl1302709760108">7.1</a>).  No clinically significant drug interaction was shown with vandetanib and the potent CYP 3A4 inhibitor, itraconazole (<a href="#rowellsl1302711106311">7.2</a>). The administration of vandetanib with agents that may prolong the QT interval should be avoided (<a href="#rowellsl1302709747546">5.11</a>)  </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">BOXED WARNING SECTION</a></h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1.  Medullary Thyroid Cancer (MTC)</a></h2>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage Adjustment</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Elderly</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Concomitant Strong CYP3A4 Inducers</a></h2>
<h2><a href="#section-2.4" class="toc">2.4  Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS &amp; STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 QT Prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Ischemic Cerebrovascular Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible posterior leukoencephalopathy syndrome</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Drug Interactions</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Use in Pregnancy</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Vandetanib REMS (Risk Evaluation and Mitigation Strategy) Program</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1. Clinical Studies Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP3A4 Inducers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP3A4 Inhibitors</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drugs that Prolong the QT Interval</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1. Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3. Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4. Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5. Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1. Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3. Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 QT Prolongation</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2. Animal Pharmacology and/or Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15. REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-15.1" class="toc">16.1. Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 QT Interval</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> </a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Pregnancy and Nursing</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Drug Handling</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="rowellsl1302709849249"></a><a name="section-1"></a><p></p>
<h1>BOXED WARNING SECTION</h1>
<p class="First"><span class="Bold">WARNING: QT PROLONGATION, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">TORSADES DE POINTES</span>, AND <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">SUDDEN DEATH</span></span></p>
<p>Vandetanib can prolong the QT interval. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have been reported in patients receiving vandetanib. Vandetanib should not be used in patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and/or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> must be corrected prior to vandetanib administration and should be periodically monitored. Drugs known to prolong the QT interval should be avoided. If a drug known to prolong the QT interval must be administered, more frequent ECG monitoring is recommended.  Given the half-life of 19 days, ECGs should be obtained to monitor the QT at baseline, at 2-4 weeks and 8-12 weeks after starting treatment with vandetanib and every 3 months thereafter.  Following any dose reduction for QT prolongation, or any dose interruptions greater than 2 weeks, QT assessment should be conducted as described above. Because of the 19-day half-life, adverse reactions including a prolonged QT interval may not resolve quickly.  Monitor appropriately. Only prescribers and pharmacies certified through the vandetanib REMS education program are able to prescribe and dispense vandetanib [see <a href="#rowellsl1302708976108">Warnings and Precautions (5.15)</a>].</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1.  Medullary Thyroid Cancer (MTC)</h2>
<p class="First">Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.   	</p>
<p>Use of vandetanib in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of vandetanib. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="rowellsl1302709585483"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>The recommended daily dose is 300 mg of vandetanib taken orally. Vandetanib treatment should be continued until patients are no longer benefiting from treatment or an unacceptable toxicity occurs.  <p class="First">Vandetanib may be taken with or without food.</p>
<p>If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose.</p>
<p><span class="Bold">For Patients who have Difficulty Swallowing Solids</span></p>
<p>Vandetanib tablets should not be crushed.  If vandetanib tablets cannot be taken whole, the tablets can be dispersed in a glass containing 2 ounces of non-carbonated water and stirred for approximately 10 minutes until the tablet is dispersed (will not completely dissolve).  No other liquids should be used.  The dispersion should be swallowed immediately.  To ensure the full dose is received, any residues in the glass should be mixed again with an additional 4 ounces of non-carbonated water and swallowed.</p>
<p>The dispersion can also be administered through nasogastric or gastrostomy tubes.</p>
<p>Direct contact of crushed tablets with the skin or mucous membranes should be avoided.  If such contact occurs, wash thoroughly. Avoid exposure to crushed tablets.  </p>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709599311"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage Adjustment</h2>In the event of corrected QT interval, Fridericia (QTcF) greater than 500 ms, interrupt dosing until QTcF returns to less than 450 ms, then resume at a reduced dose.    <p class="First">For CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or greater toxicity, interrupt dosing until toxicity resolves or improves to CTCAE grade 1, and then resume at a reduced dose.</p>
<p>Because of the 19-day half-life, adverse reactions including a prolonged QT interval may not resolve quickly.  Monitor appropriately [see Warnings and Precautions (<a href="#rowellsl1302709629546">5.1-5.7</a>, <a href="#rowellsl1302709642233">5.9</a>)]. </p>
<p>The 300-mg daily dose can be reduced to 200 mg (two 100-mg tablets) and then to 100 mg for CTCAE grade 3 or greater toxicities.   </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709698171"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Elderly</h2>
<p class="First">No adjustment in starting dose is required for patients over 65 years of age.  There are limited data for patients over the age of 75. [see <a href="#rowellsl1302709698171">Dosage and Administration (2.4)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710728514"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Concomitant Strong CYP3A4 Inducers</h2>
<p class="First">Avoid the concomitant use of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital). Patients should also avoid taking St. John’s Wort. [see <a href="#rowellsl1302709747546">Warnings and Precautions (5.11)</a>and <a href="#rowellsl1302709760108">Drug Interactions (7.1)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710787733"></a><a name="section-2.4"></a><p></p>
<h2>2.4  Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The starting dose should be reduced to 200 mg in patients with moderate (creatinine clearance ≥30 to &lt;50 mL/min) and severe (creatinine clearance &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. [see <a href="#rowellsl1302709778296">Warnings and Precautions (5.12)</a>and <a href="#rowellsl1302709802296">Use in Specific Populations (8.6)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710820592"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Single dose pharmacokinetic data from volunteers with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> receiving 800 mg suggest that there were no differences in pharmacokinetics compared to patients with normal hepatic function. There are limited data in patients with liver impairment (serum bilirubin greater than 1.5 times the upper limit of normal). Vandetanib is not recommended for use in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, as safety and efficacy have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="rowellsl1302709835608"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS &amp; STRENGTHS </h1>Vandetanib 100-mg tablets are white, round, biconvex, film-coated, and intagliated with  ‘Z 100‘ on one side and plain on the reverse side.  <p class="First">Vandetanib 300-mg tablets are white, oval, biconvex, film-coated, and intagliated with ‘Z 300’ on one side and plain on the reverse side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<p class="First">Do not use in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> [see <a href="#rowellsl1302709849249">Boxed Warning</a>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709629546"></a><a name="section-5.1"></a><p></p>
<h2>5.1 QT Prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span></h2>
<p class="First">Vandetanib can prolong the QT interval in a concentration-dependent manner [see <a href="#rowellsl1302710243967">Clinical Pharmacology (12.4)</a>]. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden deaths</span> have been reported in patients administered vandetanib. </p>
<p>Vandetanib treatment should not be started in patients whose QTcF interval is greater than 450 ms. Vandetanib should not be given to patients who have a history of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span>, congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> or uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Vandetanib has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> or recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.  Vandetanib exposure is increased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The starting dose should be reduced to 200 mg in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and QT interval should be monitored closely.</p>
<p>An ECG and levels of serum potassium, calcium, magnesium and TSH should be obtained at baseline, at 2-4 weeks and 8-12 weeks after starting treatment with vandetanib and every 3 months thereafter.  Electrolytes and ECGs may require more frequent monitoring in case of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  Following any dose reduction for QT prolongation, or any dose interruptions greater than 2 weeks, QT assessments should be conducted as described above.  Serum potassium levels should be maintained at 4 mEq/L or higher (within normal range) and serum magnesium and serum calcium should be kept within normal range to reduce the risk of electrocardiogram QT prolongation. </p>
<p>Avoid using vandetanib with drugs known to prolong the <span class="product-label-link" type="condition" conceptid="4216826" conceptname="QT interval feature">electrocardiogram QT interval</span> [see Warnings and Precautions (<a href="#rowellsl1302709747546">5.11</a>) and <a href="#rowellsl1302710524514">Drug Interactions (7.3)</a>].  If such drugs are given to patients already receiving vandetanib and no alternative therapy exists, ECG monitoring of the QT interval should be performed more frequently.</p>
<p></p>Patients who develop a QTcF greater than 500 ms should stop taking vandetanib until QTcF returns to less than 450 ms.  Dosing of vandetanib can be resumed at a reduced dose [see <a href="#rowellsl1302709599311">Dosage and Administration (2.1)</a>].</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710037155"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), some leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported with vandetanib. Treatment of severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> has included systemic corticosteroids and permanent discontinuation of vandetanib. Mild to moderate <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may manifest as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, pruritis and other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (including <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> and palmar-plantar erythrodysesthesia syndrome).   Mild to moderate <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been treated with topical and systemic corticosteroids, oral antihistamines, and topical and systemic antibiotics. If CTCAE grade 3 or greater <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> occur, vandetanib treatment should be stopped until improved. Upon improvement, consideration should be given to continuing treatment at a reduced dose or permanent discontinuation of vandetanib. [see <a href="#rowellsl1302709599311">Dosage and Administration (2.1)</a>] </p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity reactions</span> are increased with vandetanib. Patients should be advised to wear sunscreen and protective clothing when exposed to the sun.  Due to the long half-life of vandetanib, protective clothing and sunscreen should continue for 4 months after discontinuation of treatment. </p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710080858"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> (ILD) or <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> has been observed with vandetanib and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported.  Consider a diagnosis of ILD in patients presenting with non-specific respiratory signs and symptoms such as <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations. Advise patients to report promptly any new or worsening respiratory symptoms. </p>
<p>Patients who develop radiological changes suggestive of ILD and have few or no symptoms may continue vandetanib therapy with close monitoring at the discretion of the treating physician.  </p>
<p>If symptoms are moderate, consider interrupting therapy until symptoms improve. The use of corticosteroids and antibiotics may be indicated.</p>
<p>For cases where symptoms of ILD are severe, discontinue vandetanib therapy and the use of corticosteroids and antibiotics may be indicated until clinical symptoms resolve. Even upon resolution of severe ILD, permanent discontinuation of vandetanib should be considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710113874"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Ischemic Cerebrovascular Events</h2>
<p class="First">Ischemic cerebrovascular events have been observed with vandetanib and some cases have been fatal.  In the randomized medullary thyroid cancer (MTC) study, ischemic cerebrovascular events were observed more frequently with vandetanib compared to placebo (1.3% compared to 0%) and no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported.  The safety of resumption of vandetanib therapy after resolution of an ischemic cerebrovascular event has not been studied. Discontinue vandetanib in patients who experience a severe ischemic cerebrovascular event.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710125889"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">Serious hemorrhagic events, which in some cases were fatal, have been observed with vandetanib.  There were no fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in the randomized MTC study.  Three patients died of fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events while on vandetanib therapy in clinical studies.  Do not administer vandetanib to patients with recent history of <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> of ≥ 1/2 teaspoon of red blood.  Discontinue vandetanib in patients with severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710136077"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> has been observed with vandetanib and some cases have been fatal.  Discontinuation of vandetanib may be necessary in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> may not be reversible upon stopping vandetanib.  Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710146139"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was observed in patients who received vandetanib. Routine anti-diarrheal agents are recommended. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may cause <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>. Since QT prolongation is seen with vandetanib, serum electrolytes and ECGs should be carefully monitored in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. [see <a href="#rowellsl1302709629546">Warnings and Precautions (5.1)</a>]  If severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> develops, vandetanib treatment should be stopped until <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> improves. Upon improvement, treatment with vandetanib should be resumed at a reduced dose [see <a href="#rowellsl1302709599311">Dosage and Administration (2.1)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710158577"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">In the randomized MTC study where 90% of the patients enrolled had prior thyroidectomy, increases in the dose of the thyroid replacement therapy were required in 49% of the patients randomized to vandetanib compared to 17% of the patients randomized to placebo.  Thyroid-stimulating hormone (TSH) should be obtained at baseline, at 2 to 4 weeks and 8 to 12 weeks after starting treatment with vandetanib and every 3 months thereafter. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> occur, thyroid hormone levels should be examined and thyroid replacement therapy should be adjusted accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709642233"></a><a name="section-5.9"></a><p></p>
<h2>5.9  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, has been observed with vandetanib. All patients should be monitored for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and it should be controlled as appropriate. Dose reduction or interruption may be necessary.  If high blood pressure cannot be controlled, vandetanib should not be restarted [see <a href="#rowellsl1302709599311">Dosage and Administration (2.1)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710180717"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible posterior leukoencephalopathy syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible posterior leukoencephalopathy syndrome</span> (RPLS), a syndrome of subcortical vasogenic <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> diagnosed by an MRI of the brain, has been observed with vandetanib. This syndrome should be considered in any patient presenting with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or altered mental function.  In clinical studies, three of four patients who developed RPLS while taking vandetanib, including one pediatric patient, also had <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  Discontinuation of vandetanib treatment in patients with RPLS should be considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709747546"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Drug Interactions</h2>
<p class="First">The administration of vandetanib with agents that are strong CYP3A4 inducers should be avoided [see <a href="#rowellsl1302710728514">Dosage and Administration (2.3)</a>and <a href="#rowellsl1302709760108">Drug Interactions (7.1)</a>].  </p>
<p>The administration of vandetanib with anti-arrhythmic drugs (including, but not limited to amiodarone, disopyramide, procainamide, sotalol, dofetilide) and other drugs that may prolong the QT interval (including but not limited to cloroquine, clarithromycin, dolasetron, granisetron, haloperidol, methadone, moxifloxacin, and pimozide) should be avoided [see <a href="#rowellsl1302710524514">Drug Interactions (7.3)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709778296"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Vandetanib exposure is increased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The starting dose should be reduced to 200 mg in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and QT interval should be monitored closely.  There is no information available for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring dialysis. [see <a href="#rowellsl1302709849249">Boxed Warning</a>, <a href="#rowellsl1302710787733">Dosage and Administration (2.4)</a>and <a href="#rowellsl1302709802296">Use in Specific Populations (8.6)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302711267014"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Vandetanib is not recommended for use in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, as safety and efficacy have not been established.  [see <a href="#rowellsl1302710820592">Dosage and Administration (2.5)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710192655"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Use in Pregnancy</h2>Vandetanib can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women using vandetanib. In nonclinical studies in rats, vandetanib was embryotoxic, fetotoxic, and teratogenic, at exposures equivalent to or lower than those expected at the recommended human dose of 300 mg/day.  As expected from its pharmacological actions, vandetanib has shown significant effects on all stages of female reproduction in rats.      <p class="First">If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during treatment with vandetanib.  Women should be advised that they must use effective contraception to prevent pregnancy during treatment and for at least four months following the last dose of vandetanib [see <a href="#rowellsl1302710210077">Use in Specific Populations (8.1)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302708976108"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Vandetanib REMS (Risk Evaluation and Mitigation Strategy) Program</h2>
<p class="First">Because of the risk of QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, vandetanib is available only through a restricted distribution program called Vandetanib REMS Program.  Only prescribers and pharmacies certified with the program are able to prescribe and dispense vandetanib.  </p>
<p>An overview of the requirements for prescribers and pharmacies is included below.</p>
<ul>
<li>To be certified, prescribers must review the educational materials, agree to comply with the REMS requirements and enroll in the program.</li>
<li><p class="First">To be certified, pharmacies that dispense vandetanib must enroll in the program, train their pharmacy staff to verify that each prescription is written by a certified prescriber before dispensing to a patient, and agree to comply with the REMS requirements.</p></li>
</ul>
<p>To learn about the specific REMS requirements and to enroll in the Vandetanib REMS Program call 1-800-236-9933 or visit www.vandetanibrems.com.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<p class="First">The most commonly reported adverse drug reactions (&gt;20%) have been <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. The most common laboratory abnormalities (&gt;20%) were decreased calcium, increased ALT, and decreased glucose [see <a href="#rowellsl1302709599311">Dosage and Administration (2.1)</a>and Warnings and Precautions (<a href="#rowellsl1302710037155">5.2</a>, <a href="#rowellsl1302710080858">5.3 </a>and <a href="#rowellsl1302709642233">5.9</a>)].</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710996139"></a><a name="section-6.1"></a><p></p>
<h2>6.1. Clinical Studies Experience</h2>
<p class="First">Patients with unresectable locally advanced or metastatic medullary thyroid cancer were treated with vandetanib 300 mg (n=231) or Placebo (n= 99).  Patients with investigator-determined progression or patients who continued treatment after the data cut-off could receive open label vandetanib.  The following adverse reactions have been reported. [see <a href="#rowellsl1302711017733">Clinical Studies (14)</a>] </p>
<p><span class="Bold">Table 1 - Adverse Reactions in <span class="Underline">&gt;</span>10% of Patients on Vandetanib During Randomized Treatment</span></p>
<table frame="hsides">
<colgroup>
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
</colgroup>
<thead><tr class="Botrule First Last">
<th align="left">Preferred Term</th>
<th align="center" colspan="2" valign="middle">Vandetanib 300 mg N=231</th>
<th align="center" colspan="2">Placebo N=99</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, generalized, macular, maculo-papular, papular, pruritic, exfoliative, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">dermatitis bullous</span>, generalized <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">lower abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>69% had QT prolongation &gt;450ms and 7% had QT prolongation &gt;500ms by ECG using Fridericia correction.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><p class="First"></p></td>
<td align="left"><p class="First">All Grades</p></td>
<td align="left"><p class="First">Grade 3–4</p></td>
<td align="left"><p class="First">All Grades</p></td>
<td align="left"><p class="First">Grade 3–4</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></p></td>
<td align="left"><p class="First">132 (57%)</p></td>
<td align="left"><p class="First">26 (11%)</p></td>
<td align="left"><p class="First">27 (27%)</p></td>
<td align="left"><p class="First">2 (2%)</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td align="left"><p class="First">123 (53%)</p></td>
<td align="left"><p class="First">11 (5%)</p></td>
<td align="left"><p class="First">12 (12%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">Dermatitis Acneiform</span>/<span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></p></td>
<td align="left"><p class="First">81 (35%)</p></td>
<td align="left"><p class="First">2 (1%)</p></td>
<td align="left"><p class="First">7 (7%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="left"><p class="First">77 (33%)</p></td>
<td align="left"><p class="First">2 (1%)</p></td>
<td align="left"><p class="First">16 (16%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>/<span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">Hypertensive Crisis</span>/<span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">Accelerated Hypertension</span></p></td>
<td align="left"><p class="First">76 (33%)</p></td>
<td align="left"><p class="First">20 (9%)</p></td>
<td align="left"><p class="First">5 (5%)</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="left"><p class="First">59 (26%)</p></td>
<td align="left"><p class="First">2 (1%)</p></td>
<td align="left"><p class="First">9 (9%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="left"><p class="First">55 (24%)</p></td>
<td align="left"><p class="First">13 (6%)</p></td>
<td align="left"><p class="First">23 (23%)</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td align="left"><p class="First">49 (21%)</p></td>
<td align="left"><p class="First">10 (4%)</p></td>
<td align="left"><p class="First">12 (12%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td align="left"><p class="First">48 (21%)</p></td>
<td align="left"><p class="First">6 (3%)</p></td>
<td align="left"><p class="First">11 (11%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span></p></td>
<td align="left"><p class="First">35 (15%)</p></td>
<td align="left">0</td>
<td align="left">5 (5%)</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="left"><p class="First">34 (15%)</p></td>
<td align="left"><p class="First">2 (1%)</p></td>
<td align="left"><p class="First">7 (7%)</p></td>
<td align="left">0</td>
</tr>
<tr>
<td align="left"><p class="First">Asthensia</p></td>
<td align="left"><p class="First">34 (15%)</p></td>
<td align="left"><p class="First">6 (3%)</p></td>
<td align="left"><p class="First">11 (11%)</p></td>
<td align="left">1 (1%)</td>
</tr>
<tr>
<td align="left"><p class="First">ECG <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">QT Prolonged</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td align="left"><p class="First">33 (14%)</p></td>
<td align="left"><p class="First">18 (8%)</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity Reaction</span></p></td>
<td align="left"><p class="First">31 (13%)</p></td>
<td align="left"><p class="First">4 (2%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td align="left"><p class="First">30 (13%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">10 (10%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td align="left"><p class="First">26 (11%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">10 (10%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="left"><p class="First">25 (11%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">4 (4%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p></td>
<td align="left"><p class="First">25 (11%)</p></td>
<td align="left"><p class="First">4 (2%)</p></td>
<td align="left">3 (3%)</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td align="left"><p class="First">25 (11%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">10 (10%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td align="left"><p class="First">25 (11%)</p></td>
<td align="left"><p class="First">3 (1%)</p></td>
<td align="left"><p class="First">4 (4%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></p></td>
<td align="left"><p class="First">24 (10%)</p></td>
<td align="left"><p class="First">2 (1%)</p></td>
<td align="left"><p class="First">9 (9%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></p></td>
<td align="left"><p class="First">23 (10%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">2 (2%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td align="left"><p class="First">22 (10%)</p></td>
<td align="left"><p class="First">4 (2%)</p></td>
<td align="left"><p class="First">3 (3%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>Adverse reactions resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients receiving vandetanib (N=5) were <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.  Adverse reactions resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients receiving placebo were <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (1%) and <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (1%).    In addition there was one <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> and one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>, in patients receiving vandetanib after data cut-off.  Causes of discontinuation in vandetanib-treated patients in &gt;1 patient included <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, prolonged QT interval, increase in creatinine and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>. Serious adverse events in vandetanib-treated patients in &gt;2% of patients included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Clinically important uncommon adverse drug reactions in patients who received vandetanib versus patients who received placebo included <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (0.4% vs. 0%) and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (0.9% vs. 0%). In the integrated summary of safety database, the most common cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients who received vandetanib was <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>The incidence of Grade 1-2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events was 14% in patients receiving vandetanib compared with 7% on placebo in the randomized portion of the medullary thyroid cancer (MTC) study.  The incidence was similar in the 300 mg monotherapy safety program with a 13% incidence.  <p><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> was more common in patients who received vandetanib versus patients who received placebo for medullary thyroid cancer (9% vs. 1%, respectively). Scheduled slit lamp examinations have revealed corneal opacities (vortex keratopathies) in treated patients, which can lead to halos and decreased visual acuity.  It is unknown if this will improve after discontinuation. Ophthalmologic examination, including slit lamp, is recommended in patients who report visual changes.  If a patient has <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, do not drive or operate machinery.</p>
<p>Table 2 provides the frequency and severity of laboratory abnormalities reported for patients with medullary thyroid cancer receiving randomized treatment with vandetanib or placebo. </p>
<table frame="hsides">
<caption><span>Table 2 - Laboratory Abnormalities in Patients with MTC</span></caption>
<colgroup>
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
</colgroup>
<thead><tr class="Botrule First Last">
<th align="left">Laboratory Parameter</th>
<th align="center" colspan="2">Vandetanib 300 mg</th>
<th align="center" colspan="2">Placebo N=99</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"></td>
<td align="left"><p class="First">All Grades</p></td>
<td align="left"><p class="First">Grade 3–4</p></td>
<td align="left"><p class="First">All Grades</p></td>
<td align="left"><p class="First">Grade 3–4</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="Bold">Chemistries</span></p></td>
<td align="left" colspan="4"></td>
</tr>
<tr>
<td align="left"><p class="First">Calcium Decreased</p></td>
<td align="left"><p class="First">132 (57%)</p></td>
<td align="left"><p class="First">13 (6%)</p></td>
<td align="left"><p class="First">25 (25%)</p></td>
<td align="left"><p class="First">3 (3%)</p></td>
</tr>
<tr>
<td align="left"><p class="First">ALT Increased</p></td>
<td align="left"><p class="First">118 (51%)</p></td>
<td align="left"><p class="First">4 (2%)</p></td>
<td align="left"><p class="First">19 (19%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Glucose Decreased</p></td>
<td align="left"><p class="First">55 (24%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">7 (7%)</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td align="left"><p class="First">Creatinine Increased</p></td>
<td align="left"><p class="First">38 (16%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Bilirubin Increased</p></td>
<td align="left"><p class="First">29 (13%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">17 (17%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Magnesium Decreased</p></td>
<td align="left"><p class="First">17 (17%)</p></td>
<td align="left"><p class="First">1 (&lt;1%)</p></td>
<td align="left"><p class="First">2 (2%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Calcium Increased</p></td>
<td align="left"><p class="First">16 (7%)</p></td>
<td align="left"><p class="First">2 (1%)</p></td>
<td align="left"><p class="First">9 (9%)</p></td>
<td align="left"><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td align="left"><p class="First">Potassium Decreased</p></td>
<td align="left"><p class="First">15 (6%)</p></td>
<td align="left"><p class="First">1 (&lt;1%)</p></td>
<td align="left"><p class="First">3 (3%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Potassium Increased</p></td>
<td align="left"><p class="First">13 (6%)</p></td>
<td align="left"><p class="First">1 (&lt;1%)</p></td>
<td align="left"><p class="First">4 (4%)</p></td>
<td align="left"><p class="First">2 (2%)</p></td>
</tr>
<tr>
<td align="left"><p class="First">Glucose Increased</p></td>
<td align="left"><p class="First">12 (5%)</p></td>
<td align="left"><p class="First">4 (2%)</p></td>
<td align="left"><p class="First">7 (7%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Magnesium Increased</p></td>
<td align="left"><p class="First">6 (3%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">4 (4%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="Bold">Hematologic</span></p></td>
<td align="left" colspan="4"></td>
</tr>
<tr>
<td align="left"><p class="First">WBC Decreased</p></td>
<td align="left"><p class="First">45 (19%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">25 (25%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin Decreased</span></p></td>
<td align="left"><p class="First">31 (13%)</p></td>
<td align="left"><p class="First">1 (&lt;1%)</p></td>
<td align="left"><p class="First">19 (19%)</p></td>
<td align="left"><p class="First">2 (2%)</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> Decreased</p></td>
<td align="left"><p class="First">21 (10%)</p></td>
<td align="left"><p class="First">1 (&lt;1%)</p></td>
<td align="left"><p class="First">5 (5%)</p></td>
<td align="left"><p class="First">2 (2%)</p></td>
</tr>
<tr class="Last">
<td align="left"><p class="First">Platelets Decreased</p></td>
<td align="left"><p class="First">18 (9%)</p></td>
<td align="left"><p class="First">0</p></td>
<td align="left"><p class="First">3 (3%)</p></td>
<td align="left"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> elevations occurred in 51% of patients on vandetanib in the randomized medullary thyroid cancer (MTC) study. Grade 3-4 ALT elevations were seen in 2% of patients and no patients had a concomitant increase in bilirubin. Elevations in ALT have resulted in temporary discontinuation of vandetanib.  However, 16 of 22 patients with a grade 2 elevation in ALT continued 300 mg vandetanib. Seven patients who continued vandetanib had a normal ALT within 6 months. In the protocol, ALT was monitored every 3 months and more frequently as indicated.  </p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709760108"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP3A4 Inducers</h2>
<p class="First">Drugs that are CYP3A4 inducers can alter vandetanib plasma concentrations. The concomitant use of known strong CYP3A4 inducers should be avoided while receiving vandetanib therapy. St. John’s Wort may decrease vandetanib exposure unpredictably and should be avoided [see <a href="#rowellsl1302710728514">Dosage and Administration (2.3)</a>and <a href="#rowellsl1302709747546">Warnings and Precautions (5.11)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302711106311"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP3A4 Inhibitors</h2>
<p class="First">In healthy subjects, no clinically significant interaction was shown between vandetanib and the potent CYP3A4 inhibitor, itraconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710524514"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Drugs that Prolong the QT Interval</h2>
<p class="First">The administration of vandetanib with agents that may prolong the QT interval should be avoided [see <a href="#rowellsl1302709747546">Warnings and Precautions (5.11)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="rowellsl1302710210077"></a><a name="section-8.1"></a><p></p>
<h2>8.1. Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span>[see <a href="#rowellsl1302710192655">Warnings and Precautions (5.14)</a>].</p>
<p>Vandetanib can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of vandetanib in pregnant women. Vandetanib is embryotoxic, fetotoxic, and teratogenic to rats, at exposures equivalent to or lower than those expected at the recommended human dose of 300 mg/day. When vandetanib was administered to female rats prior to mating and through the first week of pregnancy, there were increases in pre-implantation loss and post-implantation loss resulting in a significant reduction in the number of live embryos.  This dose administered to rats during organogenesis, caused an increase in post-implantation loss including embryofetal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Vandetanib caused total litter loss when administered at a dose of 25 mg/kg/day during organogenesis until expected parturition. When administered during organogenesis, vandetanib doses of 1, 10 and 25 mg/kg/day (approximately 0.03, 0.4, and 1.0 times respectively, the Cmax in patients with cancer at the recommended human dose) caused malformations of the heart vessels and delayed ossification of the skull, vertebrae and sternum, indicating delayed fetal development. A no effect level for these malformations was not identified in this study.  In a rat pre- and post-natal development study, at doses producing maternal toxicity (1 and 10 mg/kg/day) during gestation and/or lactation, vandetanib, decreased pup survival, and/or reduced post-natal pup growth. Reduced post-natal pup growth was associated with a delay in physical development.  </p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid pregnancy while taking vandetanib and for at least four months following the last dose of vandetanib.  </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3. Nursing Mothers</h2>
<p class="First">In nonclinical studies, vandetanib was excreted in rat milk and found in plasma of pups following dosing to lactating rats. Vandetanib transfer in breast milk resulted in relatively constant exposure in pups due to the long half-life of the drug. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from vandetanib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4. Pediatric Use</h2>
<p class="First">Safety and efficacy of vandetanib in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5. Geriatric Use</h2>
<p class="First">In total, 18% of medullary thyroid cancer patients treated with vandetanib were age 65 years or older, and 3% were 75 years and older. No overall differences in safety and efficacy were observed between elderly and younger patients.  No adjustment in starting dose is required for patients over 65 years of age. There are limited data for patients over the age of 75 years.   </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302709802296"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The pharmacokinetics of vandetanib were evaluated after a single dose of 800 mg in subjects with mild (n = 6), moderate (n = 8), and severe (n = 6) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and normal (n = 10) renal function. Subjects with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had comparable mean AUC and clearance values to those with normal renal function. In subjects with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the average AUC of vandetanib increased by 39% and 41%, respectively, compared to patients with normal renal function.    </p>
<p>The starting dose should be reduced to 200 mg in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <a href="#rowellsl1302710787733">Dosage and Administration (2.4)</a>and <a href="#rowellsl1302709778296">Warning and Precautions (5.12)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The pharmacokinetics of vandetanib were evaluated after a single dose of 800 mg in subjects with mild (n = 8), moderate (n = 7), and severe (n = 6) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and normal hepatic function (n = 5). Subjects with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had comparable mean AUC and clearance values to those with normal hepatic function.   </p>
<p>There are limited data in patients with liver impairment (serum bilirubin greater than 1.5 times the upper limit of normal). Vandetanib is not recommended for use in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, as safety and efficacy have not been established. [see <a href="#rowellsl1302710820592">Dosage and Administration (2.5)</a>and <a href="#rowellsl1302711267014">Warnings and Precautions (5.13)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">There is no specific treatment in the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with vandetanib and possible symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have not been established. Because of the 19-day half-life, adverse reactions may not resolve quickly.  In phase 1 clinical trials, a limited number of patients were treated with daily doses of up to 600 mg and healthy volunteers with daily doses up to 1200 mg. An increase in the frequency and severity of some adverse reactions, like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, was observed at multiple doses at and above 300 mg in healthy volunteer studies and in patients. In addition the possibility of QTc prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> should be considered.</p>
<p>Adverse reactions associated with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are to be treated symptomatically; in particular, severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> must be managed appropriately. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, further doses of vandetanib must be interrupted, and appropriate measures taken to assure that an adverse event has not occurred, i.e., ECG within 24 hours to determine QTc prolongation [see <a href="#rowellsl1302709599311">Dosage and Administration (2.1)</a>].</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">Vandetanib tablets for daily oral administration are available in two dosage strengths, 100 mg and 300 mg, containing 100 mg and 300 mg of vandetanib, respectively.  The tablet cores contain the following inactive ingredients: Tablet core: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate. The tablet film-coat contains the following inactive ingredients: hypromellose 2910, macrogol 300, and titanium dioxide E171.  </p>
<p>Vandetanib is chemically described as N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy]quinazolin-4-amine.   </p>
<p>The structural and molecular formulas are:</p>
<div class="Figure"><img alt="Vandetanib Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515&amp;name=vandetanib-chemicalstructure-01.jpg"></div>
<p>C<span class="Sub">22</span>H<span class="Sub">24</span>BrFN<span class="Sub">4</span>O<span class="Sub">2</span></p>
<p>Vandetanib has a molecular weight of 475.36. Vandetanib exhibits pH-dependent solubility, with increased solubility at lower pH. Vandetanib is practically insoluble in water with a value of 0.008 mg/mL at 25°C (77°F ).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1. Mechanism of Action</h2>
<p class="First">Vandetanib is a tyrosine kinase inhibitor. <span class="Italics">In vitro </span>studies have shown that vandetanib inhibits the activity of tyrosine kinases including members of the epidermal growth factor receptor (EGFR) family, vascular endothelial cell growth factor (VEGF) receptors, rearranged during transfection (RET), protein tyrosine kinase 6 (BRK), TIE2, members of the EPH receptors kinase family, and members of the Src family of tyrosine kinases.  Vandetanib inhibits endothelial cell migration, proliferation, survival and new blood vessel formation in <span class="Italics">in vitro</span> models of angiogenesis.  Vandetanib inhibits EGFR-dependent cell survival <span class="Italics">in vitro</span>.  In addition, vandetanib inhibits epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells.  </p>
<p><span class="Italics">In vivo </span>vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> in mouse models of cancer.</p>
<p>There is no evidence of a relationship between RET mutations and efficacy with vandetanib.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.2"></a><p></p>
<h2>12.3. Pharmacokinetics</h2>
<p class="First">A population pharmacokinetic analysis of vandetanib was conducted in 231 patients with MTC following oral administration of 300 mg daily doses.  The pharmacokinetics of vandetanib at the 300 mg dose in MTC patients are characterized by a mean clearance of approximately 13.2 L/h, a mean volume of distribution of approximately 7450 L, and a median plasma half-life of 19 days.</p>
<p><span class="Italics">Absorption</span></p>
<p>Following oral administration of vandetanib, absorption is slow with peak plasma concentrations typically achieved at a median of 6 hours, range 4-10 hours, after dosing. Vandetanib accumulates approximately 8-fold on multiple dosing with steady state achieved from approximately 3 months.</p>
<p>Exposure to vandetanib is unaffected by food.</p>
<p><span class="Italics">Distribution</span></p>
<p> Vandetanib binds to human serum albumin and α1-acid-glycoprotein with <span class="Italics">in vitro</span> protein binding being approximately 90%.  In ex vivo plasma samples from colorectal cancer patients at steady state exposure after 300 mg once daily, the mean percentage protein binding was 93.7% (range 92.2 to 95.7%).</p>
<p><span class="Italics">Metabolism</span></p>
<p>Following oral dosing of <span class="Sup">14</span>C-vandetanib, unchanged vandentanib and metabolites vandetanib N-oxide and N-desmethyl vandetanib were detected in plasma, urine and feces. A glucuronide conjugate was seen as a minor metabolite in excreta only. N-desmethyl-vandetanib is primarily produced by CYP3A4 and vandetanib-N-oxide by flavin–containing monooxygenase enzymes FMO1 and FMO3. N-desmethyl-vandetanib and vandetanib-N-oxide circulate at concentrations of approximately 7-17.1% and 1.4-2.2%, respectively, of those of vandetanib.</p>
<p><span class="Italics">Excretion</span></p>
<p>Within a 21-day collection period after a single dose of <span class="Sup">14</span>C-vandetanib, approximately 69% was recovered with 44% in feces and 25% in urine. Excretion of the dose was slow and further excretion beyond 21 days would be expected based on the plasma half-life.</p>
<p>Vandetanib was not a substrate of hOCT2 expressed in HEK293 cells. Vandetanib inhibits the uptake of the selective OCT2 marker substrate <span class="Sup">14</span>C-creatinine by HEK-OCT2 cells, with a mean IC<span class="Sub">50</span> of approximately 2.1 μg/mL. This is higher than vandetanib plasma concentrations (approximately 0.81 μg/mL) observed after multiple dosing at 300 mg. Inhibition of renal excretion of creatinine by vandetanib provides an explanation for increases in plasma creatinine seen in human subjects receiving vandetanib.</p>
<p><span class="Italics">Special Populations</span></p>
<p><span class="Italics">Effects of Age and Gender</span></p>
<p>In a population pharmacokinetic evaluation in cancer patients, no relationship was apparent between oral clearance and patient age or gender. </p>
<p><span class="Italics">Ethnicity</span></p>
<p>Based on a cross-study comparison in a limited number of patients, Japanese (N=3) and Chinese (N=7) patients had on average exposures that were higher than Caucasian (N=7) patients receiving the same dose.</p>
<p><span class="Italics">Pediatric</span></p>
<p>The pharmacokinetics of vandetanib have not been evaluated in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1302710243967"></a><a name="section-11.3"></a><p></p>
<h2>12.4 QT Prolongation</h2>
<p class="First">In 231 medullary thyroid cancer patients randomized to receive vandetanib 300 mg once daily in the phase 3 clinical trial, vandetanib was associated with sustained plasma concentration-dependent QT prolongation.  Based on the exposure-response relationship, the mean (90% CI) QTcF change from baseline (ΔQTcF) was 35 (33-36) ms for the 300-mg dose.  The ΔQTcF remained above 30 ms for the duration of the trial (up to 2 years).  In addition, 36% of patients experienced greater than 60 ms increase in ΔQTcF and 4.3% of patients had QTcF greater than 500 ms. Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have been reported [see <a href="#rowellsl1302709629546">Warnings and Precautions (5.1</a>, <a href="#rowellsl1302709747546">5.11</a>)].   </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been conducted with vandetanib.</p>
<p> Vandetanib was not mutagenic <span class="Italics">in vitro</span> in the bacterial reverse mutation (Ames) assay and was not clastogenic in both the <span class="Italics">in vitro</span> cytogenetic assay using human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or in the <span class="Italics">in vivo</span> rat micronucleus assay.</p>
<p> Based on nonclinical findings, male and female fertility may be impaired by treatment with vandetanib.  In a fertility study in male rats, vandetanib had no effect on copulation or fertility rate when undosed females were mated with males administered 1, 5, or 20 mg/kg/day of vandetanib (approximately 0.03, 0.22, or 0.40 times, respectively, the AUC in patients with cancer at the recommended human dose of 300 mg/day).  There was a slight decrease in the number of live embryos at 20 mg/kg/day and an increase in preimplantation loss at &gt;5 mg/kg/day. In a female fertility study, there was a trend towards increased estrus cycle irregularity, a slight reduction in pregnancy incidence and an increase in implantation loss. In a repeat-dose toxicity study in rats, there was a decrease in the number of corpora lutea in the ovaries of rats administered 75 mg/kg/day vandetanib (approximately 1.8 times the AUC in patients with cancer at the recommended human dose) for 1 month.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12.2"></a><p></p>
<h2>13.2. Animal Pharmacology and/or Toxicology</h2>
<p class="First">In an animal model of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>-healing, mice dosed with vandetanib had reduced skin-breaking strength compared with controls. This suggests that vandetanib slows but does not prevent <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. The appropriate interval between discontinuation of vandetanib and subsequent elective surgery required to avoid the risks of impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing has not been determined.</p>
<p>Nodular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span> were observed in a 6-month toxicology study in rats during treatment with ≥5 mg/kg/day vandetanib (approximately 0.22 or 0.40 times, respectively, the AUC in patients with cancer at the recommended human dose of 300 mg/day).  <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Masses</span> were palpable during clinical assessments as early as week 13, were observed in multiple organs, and were associated with hemorrhagic or inflammatory findings.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="rowellsl1302711017733"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<p class="First">A double-blind, placebo-controlled study randomized patients with unresectable locally advanced or metastatic medullary thyroid cancer to vandetanib 300 mg (n=231) versus Placebo (n=100).</p>
<p>The primary objective was demonstration of improvement in progression-free survival (PFS) with vandetanib compared to placebo.  Other endpoints included evaluation of overall survival and overall objective response rate (ORR). Centralized, independent blinded review of the imaging data was used in the assessment of PFS and ORR.  Upon objective disease progression based on the investigator’s assessment, patients were discontinued from blinded study treatment and given the option to receive open-label vandetanib.  Nineteen percent (44/231) of the patients initially randomized to vandetanib opted to receive open-label vandetanib after disease progression, and 58% (58/100) of the patients initially randomized to placebo opted to receive open-label vandetanib after disease progression.</p>
<p>The result of the PFS analysis, based on the central review RECIST assessment, showed a statistically significant improvement in PFS for patients randomized to vandetanib (Hazard Ratio (HR) = 0.35; 95% Confidence Interval (CI) = 0.24-0.53; p&lt;0.0001). Analyses in the subgroups of patients who were symptomatic or had progressed within 6 months prior to their enrollment showed similar PFS results (HR = 0.31 95% CI: 0.19, 0.53 for symptomatic patients; HR = 0.41 95% CI: 0.25, 0.66 for patients who had progressed within 6 months prior to enrollment). </p>
<p>At the time of the primary analysis of PFS, 15% of the patients had died and there was no significant difference in overall survival between the two treatment groups.  The overall objective response rate (ORR) for patients randomized to vandetanib was 44% compared to 1% for patients randomized to placebo.   All objective responses were partial responses.</p>
<div class="Figure">
<img alt="Kaplan Meier for Progression-Free Survival" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515&amp;name=vandetanib-figure-4.jpg"><p class="MultiMediaCaption">Figure 1- Progression Free Survival</p>
</div>
<table frame="hsides">
<caption><span>Table 3: Summary of key efficacy findings</span></caption>
<colgroup>
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
</colgroup>
<thead><tr class="Botrule First Last">
<th align="left">Progression-Free Survival (PFS)</th>
<th align="left">N<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</th>
<th align="left">Median PFS (95% CI)</th>
<th align="left">HR<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</th>
<th align="left">95% CI</th>
<th align="left">p-value<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>N = Number of events/number of randomized patients</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>HR= Hazard Ratio, Cox Proportional Hazards Model </dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Logrank test</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>NE = non-estimatable</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><p class="First">Vandetanib 300 mg</p></td>
<td align="left"><p class="First">59/231 (26%)</p></td>
<td align="left"><p class="First">Not reached (22.6 months, NE<a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a>)</p></td>
<td align="left"><p class="First">0.35</p></td>
<td align="left"><p class="First">0.24, 0.53</p></td>
<td align="left"><p class="First">&lt;0.0001</p></td>
</tr>
<tr class="Last">
<td align="left"><p class="First">Placebo</p></td>
<td align="left"><p class="First">41/100</p></td>
<td align="left"><p class="First">16.4 Months (8.3, 19.7)</p></td>
<td align="left" colspan="3"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="rowellsl1302711393467"></a><a name="section-14"></a><p></p>
<h1>15. REFERENCES</h1>
<ol>
<li><p class="First">NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004 165.</p></li>
<li><p class="First">OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999.  http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</p></li>
<li><p class="First">American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: Am J Health-Syst Pharm. (2006) 63:1172-1193.</p></li>
<li><p class="First">Polovich, M., White, J. M., &amp; Kelleher, L. O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING </h1>
<p class="First"><span class="Bold">100 mg Tablets </span>Available in bottles containing 30 tablets (NDC 0310–7810–30).</p>
<p><span class="Bold">300 mg Tablets</span> Available in bottles containing 30 tablets (NDC 0310–7830–30).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<h2>16.1. Storage and Handling</h2>
<p class="First">Vandetanib tablets should be stored at 25°C (77°F); excursions permitted to 15<span class="Sup">o</span>C – 30<span class="Sup">o</span>C (59<span class="Sup">o</span>F – 86<span class="Sup">o</span>F) [See USP controlled room temperature]. </p>
<p>Procedures for proper handling and disposal of anticancer drugs should be considered.  Several guidelines on this subject have been published<span class="Sup">1-4</span>. Vandetanib tablets should not be crushed.  Direct contact of crushed tablets with the skin or mucous membranes should be avoided.  If such contact occurs, wash thoroughly as outlined in the references.  Personnel should avoid exposure to crushed tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1 QT Interval</h2>
<p class="First">Vandetanib can prolong the QT interval in a concentration-dependent manner. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have been reported in patients administered vandetanib.  Patients should be advised that their electrolytes and the electrical activity of their heartbeat (via an ECG) should be monitored regularly during treatment with vandetanib.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">Patients taking vandetanib should be told they may be more susceptible to sunburn and to use appropriate sun protection (e.g., sunscreen and/or clothing) while taking vandetanib and for at least 4 months after drug discontinuation. Patients should consult their physician promptly if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span></h2>
<p class="First">Patients should be told to contact their physician promptly if they develop sudden onset or worsening of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">breathlessness</span>, persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<h2>17.4  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Patients should be informed that they may experience <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> while taking vandetanib.  Patients should also be advised to use standard anti-diarrheal medications and to seek medical attention if their <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> becomes persistent or severe.  Patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should contact their physician to have their electrolytes monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> </h2>
<p class="First">Patients should be told to contact their physician promptly if they experience <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">difficulty thinking</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.6"></a><p></p>
<h2>17.6 Pregnancy and Nursing</h2>
<p class="First">Patients of childbearing potential must be told to use effective contraception during therapy and for at least four months following their last dose of vandetanib.</p>
<p>Breast-feeding mothers are advised to discontinue nursing while receiving vandetanib therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.7"></a><p></p>
<h2>17.7 Drug Handling</h2>
<p class="First">Vandetanib tablets should not be crushed.  Direct contact of crushed tablets with the skin or mucous membranes should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-17"></a><p></p>
<h1>17.8 Medication Guide</h1>
<p class="First"><span class="Bold">MEDICATION GUIDE </span></p>
<p><span class="Bold">Vandetanib [van-DEH-tuh-nib]</span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read this Medication Guide before you start taking vandetanib and each time you get a refill. There may be new information.  This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. </p>
<p><span class="Bold">What is the most important information I should know about vandetanib?</span></p>
<p><span class="Bold">Vandetanib can cause a change in the electrical activity of your heart called QT prolongation</span>, which can cause irregular heartbeats and that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You should not take vandetanib if you have had a condition called <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> since birth.</p>
<p>Your healthcare provider should perform tests to check the levels of your <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span>, calcium, magnesium, and thyroid-stimulating hormone (TSH) as well as the electrical activity of your heart with a test called an electrocardiogram (ECG).  You should have these tests: </p>
<ul>
<li><p class="First">Before starting vandetanib </p></li>
<li><p class="First">Regularly during vandetanib treatment: </p></li>
</ul>
<ul class="Circle">
<li><p class="First">2 to 4 weeks after starting vandetanib </p></li>
<li><p class="First">8 to 12 weeks after starting vandetanib </p></li>
<li><p class="First">Every 3 months thereafter</p></li>
<li><p class="First">If your healthcare provider changes your dose of vandetanib</p></li>
<li><p class="First">If you start taking medicine that causes QT prolongation</p></li>
<li><p class="First">As instructed by your healthcare provider</p></li>
</ul>
<p>Your healthcare provider may stop your vandetanib treatment for a while and restart you at a lower dose if you have QT prolongation. </p>
<p><span class="Bold">Call your healthcare provider right away if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, light-headed, or feel your heart beating irregularly while taking vandetanib.   These may be symptoms related to QT prolongation. </span></p>
<p><span class="Bold">What is vandetanib?</span></p>
<p>Vandetanib is a prescription medicine used to treat medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.  It takes a long time to get rid of vandetanib from your body and you may be at risk for side effects related to vandetanib after you have stopped your treatment.</p>
<p>It is not known if vandetanib is safe and effective in children.</p>
<p><span class="Bold">Who should not take vandetanib?</span></p>
<p>Do not take vandetanib if you have had QT prolongation. </p>
<p><span class="Bold">What should I tell my healthcare provider before taking vandetanib? </span></p>
<p><span class="Bold">Before you take vandetanib, tell your healthcare provider if you:</span></p>
<ul>
<li><p class="First">have any heart problems, including a condition called congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>.</p></li>
<li><p class="First">have an irregular heartbeat</p></li>
<li><p class="First">take or have stopped taking a medicine that causes QT prolongation</p></li>
<li><p class="First">have low blood levels of potassium, calcium, or magnesium</p></li>
<li><p class="First">have high blood levels of thyroid-stimulating hormone</p></li>
<li><p class="First">have high blood pressure </p></li>
<li><p class="First">have skin problems</p></li>
<li><p class="First">have a history of breathing problems </p></li>
<li><p class="First">have a recent history of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p></li>
<li><p class="First">have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p></li>
<li><p class="First">have liver problems</p></li>
<li><p class="First">have kidney problems</p></li>
<li><p class="First">have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or are being treated for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></p></li>
<li>
<p class="First">are pregnant or plan to become pregnant.  Vandetanib can cause harm to your unborn baby.  Talk to your healthcare provider if you are pregnant or plan to become pregnant. </p>
<ul class="Circle">
<li><p class="First">If you are able to become pregnant, you should use effective birth control during your treatment with vandetanib and for at least 4 months after your last dose of vandetanib. </p></li>
<li><p class="First">Talk to your healthcare provider about birth control methods to prevent pregnancy while you are taking vandetanib.</p></li>
</ul>
</li>
<li><p class="First">are breastfeeding or plan to breastfeed.  It is not known if vandetanib passes into your breast milk. You and your healthcare provider should decide if you will take vandetanib or breastfeed. You should not do both. </p></li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Vandetanib and other medicines may affect each other causing side effects.  </p>
<p>Especially tell your healthcare provider if you take:</p>
<ul>
<li><p class="First">St. John’s Wort. You should not take St. John’s Wort while taking vandetanib.</p></li>
<li><p class="First">certain medicines that can affect how your liver breaks down medicine</p></li>
<li><p class="First">a medicine for your heart</p></li>
</ul>
<p>Ask your healthcare provider if you are not sure if your medicine is one listed above.</p>
<p><span class="Bold">Do not take other medicines while taking vandetanib until you have talked with your healthcare provider or pharmacist. </span></p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take vandetanib?</span></p>
<ul>
<li><p class="First">Take vandetanib exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking vandetanib unless your healthcare provider tells you to.</p></li>
<li><p class="First">Vandetanib may be taken with or without food.</p></li>
<li><p class="First">Swallow vandetanib tablets whole with water.</p></li>
<li><p class="First">Do not crush or chew vandetanib tablets.  If vandetanib tablets are accidentally crushed, contact with skin should be avoided.  If contact occurs, wash affected areas well with water.</p></li>
<li>
<p class="First">If you cannot swallow vandetanib tablets whole: </p>
<ul class="Circle">
<li><p class="First">place your dose of vandetanib in a glass that contains 2 ounces of noncarbonated water (no other liquids should be used).</p></li>
<li><p class="First">stir the vandetanib tablet(s) and water mixture for about 10 minutes or until the tablet(s) are in very small pieces (the tablets will not completely dissolve).</p></li>
<li><p class="First">swallow vandetanib and water mixture right away.  </p></li>
<li><p class="First">if any vandetanib and water mixture  remains in the glass, mix with an additional 4 ounces of noncarbonated water and swallow the mixture to make sure that you take your full dose of vandetanib.  </p></li>
</ul>
</li>
<li>
<p class="First">If you miss a dose and your next dose is in:</p>
<ul class="Circle">
<li><p class="First">less than 12 hours, take your next dose at the normal time. Do not make up for the missed dose. </p></li>
<li><p class="First">12 hours or more, take the missed dose as soon as you remember. Take the next dose at the normal time. </p></li>
</ul>
</li>
</ul>
<p>Call your healthcare provider right away if you take too much vandetanib.</p>
<ul>
<li><p class="First">During treatment with vandetanib, your healthcare provider should check your blood and heart for side effects.  See “What is the most important information I should know about vandetanib??</p></li>
<li><p class="First">Your healthcare provider should check your blood pressure regularly during your treatment with vandetanib.</p></li>
</ul>
<p><span class="Bold">What should I avoid while taking vandetanib?</span></p>
<ul>
<li><p class="First">Limit exposure to the sun.  Vandetanib can make your skin sensitive to the sun.  While taking vandetanib and for 4 months after stopping your vandetanib treatment, use sun block and wear clothes that cover your skin, including your head, arms and legs when you go outdoors.</p></li>
<li><p class="First">Use caution before driving or using machinery.  Keep in mind vandetanib may make you feel tired, weak, or cause <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p></li>
</ul>
<p><span class="Bold">What are the possible side effects of vandetanib? </span></p>
<p><span class="Bold">Vandetanib may cause serious side effects, including: </span></p>
<ul>
<li><p class="First">See “<span class="Bold">What is the most important information I should know about vandetanib?</span>? </p></li>
<li>
<p class="First"><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span></p>
<p>Vandetanib can cause a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>, called <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> or other serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that may affect any part of your body. These serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may be life threatening and you may need to be treated in a hospital.  Call your healthcare provider right away if you experience any of these symptoms.</p>
</li>
</ul>
<ul>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> or <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> on your skin</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> or sores in your mouth</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Peeling</span> of your skin</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></li>
<li><p class="First">Muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, hands, or soles of your feet</p></li>
</ul>
<ul>
<li><p class="First"><span class="Bold">Breathing problems (<span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>). </span>Vandetanib may cause a breathing problem called <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your healthcare provider right away if you experience sudden or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p></li>
<li>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>.</span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span> have been reported in some people who have taken vandetanib and in some cases have caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Stop taking vandetanib and call your healthcare provider right away if you have symptoms of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> which may include:</p>
<ul class="Circle">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of the face, arm or leg, especially on one side of the body</p></li>
<li><p class="First">sudden <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, trouble speaking or understanding</p></li>
<li><p class="First">sudden trouble seeing in one or both eyes  </p></li>
<li><p class="First">sudden trouble walking, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of balance or coordination</p></li>
<li><p class="First">sudden, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p></li>
</ul>
</li>
</ul>
<ul>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>. </span><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can happen during your treatment with vandetanib. Tell your healthcare provider right away if you have severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while you are taking vandetanib.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>.</span>  Vandetanib can cause <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  You may have to stop taking vandetanib if you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> may not be reversible after stopping vandetanib.  Your healthcare provider should monitor you for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is often a symptom of medullary thyroid cancer.  Vandetanib can also cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or make <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> worse.  Your healthcare provider should check your blood levels to monitor your electrolytes more frequently if you have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p></li>
<li><p class="First"><span class="Bold">Thyroid hormones.  </span>You can have changes in your thyroid hormone when taking vandetanib. Your healthcare provider should monitor your thyroid hormone levels while taking vandetanib.</p></li>
<li><p class="First"><span class="Bold">High blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>).</span>  If you develop high blood pressure or your high blood pressure gets worse, your healthcare provider may lower your dose of vandetanib or tell you to stop taking vandetanib until your blood pressure is under control.  Your healthcare provider may prescribe another medicine to control your high blood pressure.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS).</span>  A condition called <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span> can happen while taking vandetanib.  Call your healthcare provider right away if you have:</p></li>
</ul>
<ul class="Circle">
<li><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></p></li>
<li><p class="First">changes in vision</p></li>
<li><p class="First">problems thinking</p></li>
</ul>
<p><span class="Bold">The most common side effects of vandetanib include:</span></p>
<ul>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p></li>
<li><p class="First">high blood pressure</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p></li>
<li><p class="First">feeling tired</p></li>
<li><p class="First">loss of appetite</p></li>
<li><p class="First">stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of vandetanib.  For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store vandetanib?</span></p>
<ul>
<li><p class="First">Store vandetanib tablets at 59°F to 86°F (15°C to 30°C). </p></li>
<li><p class="First">Safely throw away medicine that is out of date or that you no longer need. Ask your pharmacist how to safely throw away vandetanib tablets.</p></li>
</ul>
<p><span class="Bold">Keep vandetanib and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about vandetanib.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use vandetanib for a condition for which it was not prescribed. Do not give vandetanib to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes important information about vandetanib. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about vandetanib that is written for health professionals. </p>
<p>For more information, go to www.vandetanib.com or call 1-800-236-9933.</p>
<p><span class="Bold">What are the ingredients in vandetanib?</span></p>
<p>Active ingredient: vandetanib </p>
<p>Inactive ingredients:</p>
<p><span class="Bold">Tablet core:</span> calcium hydrogen phosphate dihydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate  <span class="Bold"></span></p>
<p><span class="Bold">Tablet coating:</span>hypromellose 2910, macrogol 300, and titanium dioxide E171 </p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Distirbuted by:</p>
<p>AstraZeneca Pharmaceuticals LP </p>
<p>Wilmington, DE 19850 </p>
<p>Issued 04-06–2011</p>
<p>©AstraZeneca 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"></p>
<div class="Figure"><img alt="30 tablet bottle label for 100 mg tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515&amp;name=vandetanib-draftcontainer100mg.jpg"></div>
<p></p>
<div class="Figure"><img alt="30 tablet bottle label for 300 mg tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515&amp;name=vandetanib-draftcontainer300mg.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANDETANIB 		
					</strong><br><span class="contentTableReg">vandetanib tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-7810</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VANDETANIB</strong> (VANDETANIB) </td>
<td class="formItem">VANDETANIB</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 300</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Z;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-7810-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022405</td>
<td class="formItem">04/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANDETANIB 		
					</strong><br><span class="contentTableReg">vandetanib tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-7830</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VANDETANIB</strong> (VANDETANIB) </td>
<td class="formItem">VANDETANIB</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 300</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Z;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-7830-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022405</td>
<td class="formItem">04/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>AstraZeneca Pharmaceuticals LP
							(054743190)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>AstraZeneca PLC (230790719)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">IPR Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">156931248</td>
<td class="formItem">MANUFACTURE(0310-7810, 0310-7830)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lonza AG</td>
<td class="formItem"></td>
<td class="formItem">480007517</td>
<td class="formItem">API MANUFACTURE(0310-7810, 0310-7830)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d1592dcf-a1ba-4c8d-50bf-c88126a930da</div>
<div>Set id: d2a87691-c9ad-4753-97a1-311fccfe6515</div>
<div>Version: 3</div>
<div>Effective Time: 20110413</div>
</div>
</div> <div class="DistributorName">AstraZeneca Pharmaceuticals LP</div></p>
</body></html>
